secwatch.observer — SEC 8-K summary
======================================

Issuer:     RAPID MICRO BIOSYSTEMS, INC. (RPID)
CIK:        0001380106
Form:       8-K
Filed at:   2022-03-04T23:59:59+00:00
Accession:  0001380106-22-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rapid Micro Biosystems FY2021 commercial revenue up 54% to $21.6M; net loss $73.5M
--------------------------------------------------------------------------------

- FY2021 total revenue $23.2M vs $16.1M; commercial revenue $21.6M (+54%); net loss $73.5M vs $37.1M.
- Q4 2021 total revenue $5.2M flat YoY; commercial revenue $4.9M; recurring revenue $2.3M (+91%).
- FY2022 commercial revenue guidance reaffirmed at $27M-$32M (25-50% growth).
- Cash, cash equivalents and investments $203.5M, no debt.
- Placed 29 new systems FY2021; cumulative placed 116, validated 84.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1380106/000138010622000007/0001380106-22-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1380106/000138010622000007/c106-20220304x8k.htm
  HTML page:      https://secwatch.observer/filing/0001380106-22-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer